Salmon calcitonin: a review of current and future therapeutic indications.
Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.
Chesnut
C H
CH
Osteoporosis Research Group, University of Washington, Seattle, WA, USA. chesnut@u.washington.edu
Azria
M
M
Silverman
S
S
Engelhardt
M
M
Olson
M
M
Mindeholm
L
L
D000328:Adult; D000368:Aged; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001862:Bone Resorption / Q000378:metabolism* / Q000503:physiopathology; D002116:Calcitonin / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000378:metabolism; D016103:Spinal Fractures / Q000517:prevention & control*; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; C028815:salmon calcitonin; D002116:Calcitonin